[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537168":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":38,"responsibleParty":50,"collaborators":24,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":24,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":24,"enrollmentInfo":62,"targetDuration":24,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Cosmetique Active International","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: holistic approach","EXPERIMENTAL","adult subjects having AK (grade I or II) lesions on the scalp and meeting specific inclusion\u002Fexclusion criteria including a Tolak® treatment planned before study start",[13],"Other: Group A: holistic approach",{"label":15,"type":16,"description":11,"interventionNames":17},"Group B: Tolak® Standard of use","ACTIVE_COMPARATOR",[18],"Other: Group B: Tolak® Standard of use",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"OTHER","2-week Lipikar Urea 30% application (once daily in the evening) + 4-week Tolak® treatment (once daily in the evening)",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"4-week Tolak® alone treatment (once daily in the evening)",[15],[29],{"name":30,"affiliation":31,"role":32},"Thomas Dirschka","CentroDerm GmbH","PRINCIPAL_INVESTIGATOR",[34],{"name":30,"role":35,"phone":36,"phoneExt":24,"email":37},"CONTACT","+49 2 02 \u002F 629337-32","s.weber@centroderm.de",[39],{"facility":31,"status":40,"city":41,"state":24,"zip":24,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":24},"RECRUITING","Wuppertal","Germany","DE",{"type":45,"coordinates":46},"Point",[47,48],7.14816,51.25627,{"lat":48,"lon":47},{"type":51,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100537168","effect-of-lipikar-urea-30-before-actinic-keratoses-treatment-100537168",false,"NCT06274320","Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment","Investigation of the Effect of a 2 Weeks Lipikar Urea 30% Application Preceding a Planned Topical 5-FU 4% Actinic Keratoses Treatment on Efficacy of 5-FU 4%","Inclusion Criteria:\n\n* diagnosis of at least 4 non-hypertrophic, non-hyperkeratotic actinic keratosis of the the scalp\n* planned treatment of actinic keratoses of the scalp with Tolak®\n* Olsen grade I or II\n\nExclusion Criteria:\n\n* known or documented intolerance to any of the ingredients of Tolak® or Lipikar Urea 30%\n* treatment of actinic keratoses in the treatment area within the past 3 months (e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.)\n* suspected invasive squamous cell cancer in the treatment area\n* chronic wounds, erosions, pre-existing inflamed or infected skin with disruption of the epidermal barrier in the treatment area current or within the last 8 weeks given systemic cancer medication or systemic treatment with 5-Fluorouracil",true,"ALL","18 Years",{"count":63,"type":64},100,"ESTIMATED","INTERVENTIONAL",[67],"NA","This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion\u002Fexclusion criteria. The purpose of the study is to evaluate a holistic management (efficacy, tolerability and lesion cosmetic outcomes) of Tolak® treatment.",[70],"Actinic Keratoses",[72,73,74],"actinic keratoses","Lipikar Urea 30%","Olsen grade","2024-06-14",{"date":77,"type":78},"2024-06-18","ACTUAL",{"date":80,"type":78},"2024-04-05",{"date":82,"type":64},"2025-06",{"name":5,"class":6},1]